Clinical trials and real-world data consistently show significant weight loss from treatment with Ozempic, Semaglutide and Tirzepatide: Unfortunately, weight regain is a well-documented phenomenon after discontinuation of treatment: SURMOUNT 4 trial- Weight regain after stopping Tirzepatide after 36 weeks versus continuation of treatment Beyond weight regain, the discontinuation of GLP-1 agonists may reverse cardiometabolic benefits: Ongoing trials (e.g., SELECT and SURPASS-CVOT) aim to clarify whether continued use is necessary for sustained cardiovascular risk reduction
Translated into practical terms, most people can expect to lose three to five pounds per month on phentermine, with the most significant losses occurring in the first few weeks before tolerance begins to develop
pH-dependent degradation mechanisms Peptides are susceptible to various degradation pathways, many of which are pH-dependent
DPN: More protocolized care (combining oral/topical + SCS where eligible)
Planning for complex generic sourcing should start 36 to 48 months before the expected LOE date
Patients should be educated about warning signs that indicate potentially serious complications requiring clinical assessment